Self-regulating networks dictate the genetic program of tumor cells

September 25, 2012

Scientists at Charité – Universitätsmedizin Berlin could explain a yet unknown regulatory network that controls the growth of tumor cells. Understanding such networks is an important task in molecular tumor biology in order to decode the relationships between the determinants defining which molecules are produced and in what quantities, in both normal and tumor cells. The study is published in the journal Molecular Systems Biology.

The growth of a tumor and its reaction to specifically targeted therapy is dictated by changes in its genetic material (mutations) encoding special signal molecules. These molecules activate the genetic program of tumor cells via branched signalingpathways and influence all processes needed for cell division, the mobility of cells and metastasis. Significant steering elements of these tumor-specific programs are called transcription factors. These are molecules that selectively control the transcription of the cell's genetic information (DNA) into and enable production of proteins . Altogether a complex network of mutually regulating transcription factors is activated.

Whereas the signal network in human tumors has already been characterized very well, it is hardly understood how transcription factors cooperate and regulate each other. In order to explain this transcription factor network, the scientists used a approach. A complex experimental data set—in which the in were systematically disrupted—was analyzed with the help of mathematical modeling. As a result, interactions within the network could be reconstructed and the network controlling tumor growth clarified.

"Contrary to a current assumption, the results show that no superordinate transcription factor exists that controls the activity of other factors as a master regulator," explains Prof. Reinhold Schäfer, head of the Laboratory for Molecular Tumor Pathology and deputy director of the Charité Comprehensive Cancer Center. Instead, two hierarchical groups of interacting factors exist. Each of them activates gene sets needed for growth and cancer-specific properties of the cells. The results indicate that new therapeutic approaches against tumors must target multiple rather than singular factors and consider the network structures.

Explore further: What causes brain cancer? Understanding glioblastoma at the genetic, molecular level

More information: Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Blüthgen N, Schäfer R. Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS. Mol Syst Biol. 2012 Jul 31;8:601. doi: 10.1038/msb.2012.32

Related Stories

What causes brain cancer? Understanding glioblastoma at the genetic, molecular level

July 6, 2011
Glioblastoma is the most common and most lethal form of brain tumor in people. Research published in the International Journal of Computational Biology and Drug Design offers a novel way to determine what biological functions ...

Researchers and colleagues identify PHF20, a regulator of gene P53

August 24, 2012
Researchers at Moffitt Cancer Center and colleagues have identified PHF20, a novel transcriptional factor, and clarified its role in maintaining the stability and transcription of p53, a gene that allows for both normal cell ...

Disappearance of genetic material allows tumor cells to grow

August 4, 2011
Malignant Sézary syndrome is characterized by the reproduction of a special type of white blood cells in the skin of male and female patients. In contrast to most other skin lymphomas, patients with Sézary syndrome ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.